Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 ( COX-2 ) inhibitor with an IC 50 value of 18 nM, it also inhibits COX1- activity with an IC 50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect In Vitro Imrecoxib (BAP-909) (0.1-10 µM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: U937 cells Concentration: 0.1 µM; 1 µM; 10 µM Incubation Time: 24 hours Result: Decreased COX-2 mRNA level. In Vivo Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours . Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat carrageenan-induced edema model Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection Result: Inhibited the edema response with different doses. Animal Model: Rat adjuvant-induced arthritis (AIA) model Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days Result: Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg. Form:Solid IC50& Target:Human COX-1 115 nM (IC 50 ) Human COX-2 18 nM (IC 50 )